Diuretic Use in Heart Failure and Outcomes

@article{Lueder2013DiureticUI,
  title={Diuretic Use in Heart Failure and Outcomes},
  author={T. G. Von Lueder and Dan Atar and Henry Krum},
  journal={Clinical Pharmacology \& Therapeutics},
  year={2013},
  volume={94}
}
Diuretics are frequently administered to relieve congestive symptoms in patients with heart failure (HF). Despite their widespread use, prospective data on the potential of diuretics to modulate HF‐related morbidity and mortality are scarce. Diuretic efficacy may be limited by adverse neurohormonal activation and by “congestion‐like” symptoms that may occur in the absence of fluid overload. Herein, we review the current knowledge on diuretic use and outcomes in HF. 

Topics from this paper

Responsiveness to loop diuretics in heart failure.
TLDR
Although loop diuretics may be life saving in patients with ADHF and pulmonary oedema, they have not been shown definitively to extend survival in patients as well as chronic HF, although they do play a critically important role in the reduction of oingema and dyspnoea.
Loop diuretic adjustments in patients with chronic heart failure: Insights from HF‐ACTION
TLDR
The initiation or discontinuation of diuretic use over a 6‐month time frame was not associated with a difference in mortality, hospitalizations, exercise, or health status outcomes, but a dose increase in HF patients was associated with worse exercise and health Status outcomes.
Tratamiento con diuréticos en la insuficiencia cardíaca aguda
TLDR
Low or "non-diuretic" doses of aldosterone antagonists have been demonstrated to confer a survival benefit in patients with heart failure and reduced ejection fraction and consequently should be prescribed in all such patients, unless contraindicated by potassium and/or renal function values.
Loop diuretic use is associated with skeletal muscle wasting in patients with heart failure.
TLDR
Loop diuretics are associated with decreased thigh and arm circumferences in patients with HF, independent of the severity of HF, and revealed for the first time the adverse effects of loop diuretic on skeletal muscle wasting.
Diuretic response in acute heart failure: clinical characteristics and prognostic significance.
TLDR
Worse diuretic response was associated with more advanced heart failure, renal impairment, diabetes, atherosclerotic disease and in-hospital worsening heart failure and predicts mortality and heart failure rehospitalization in this post hoc, hypothesis-generating study.
In-Hospital Diuretic Agent Use and Post-Discharge Clinical Outcomes in Patients Hospitalized for Worsening Heart Failure: Insights From the EVEREST Trial.
TLDR
Short-term diuretic agent exposure during hospital treatment for worsening HF was not an independent predictor of 30-day all-cause mortality and HF rehospitalization in multivariate analysis and Congestion status at hospital discharge did not modify the association between diUREtic agent dose and clinical outcomes.
Heart Failure: A Disease Complex with Challenging Therapeutics
  • J. Vincent
  • Medicine
    Clinical pharmacology and therapeutics
  • 2013
TLDR
HF with preserved ejection fraction (HFpEF) is commoner among women who may have underlying hypertension, and significant progress has been achieved in the development of lifesaving drugs for HF with reduced ejections fraction (HFrEF), however, treatment of HFpEF still poses significant challenges.
New medical therapies for heart failure
TLDR
Novel agents for HF therapy include dual-acting neurohormonal modulators, contractility-enhancing agents, vasoactive and anti-inflammatory peptides, and myocardial protectants that have the potential to enhance the armamentarium of HF therapeutics.
Can medications be safely withdrawn in patients with stable chronic heart failure? systematic review and meta-analysis.
TLDR
Current evidence discourages any attempt to discontinue RAAS inhibitors or beta-blockers in patients with stable HF, regardless of clinical and/or echocardiographic status.
Vasopressin receptor antagonists for the treatment of heart failure: a systematic review and meta-analysis of randomized controlled trials
TLDR
Vasopressin receptors antagonists may reduce body weight and increase Na but do not improve all-cause mortality, cardiovascular mortality or kidney function, and acceptability of long-term treatment side effects and hospitalization appears problematic.
...
1
2
3
...

References

SHOWING 1-10 OF 123 REFERENCES
Diuretics for heart failure
TLDR
The use of diuretics in the management of acute and chronic heart failure is reviewed and how they should be integrated with ACE inhibition is considered.
Loop Diuretic Therapy in Heart Failure: The Need for Solid Evidence on a Fluid Issue
TLDR
Results of clinical trials in the acute decompensated heart failure (ADHF) setting have been mostly neutral, and loop diuretics remain the mainstay of treatment.
Impact of Intravenous Loop Diuretics on Outcomes of Patients Hospitalized with Acute Decompensated Heart Failure: Insights from the ADHERE Registry
TLDR
The patients receiving the lower doses had a lower risk for in-hospital mortality, ICU stay, prolonged hospitalization, or adverse renal effects, and these findings suggest that future studies should evaluate strategies for minimizing exposure to high doses of diuretics.
Diuretic therapy in congestive heart failure.
TLDR
The purpose of this review is to show how understanding pharmacokinetics and pharmacodynamics results in logical diuretic use in patients with congestive heart failure.
Diuretic therapy in congestive heart failure.
  • D. Brater
  • Medicine
    Congestive heart failure
  • 2000
TLDR
The purpose of this review is to show how understanding pharmacokinetics and pharmacodynamics results in logical diuretic use in patients with congestive heart failure.
Cardiorenal Syndrome and the Role of Ultrafiltration in Heart Failure
TLDR
The aim of this review is to discuss the developments in both pharmacologic and extracorporeal methods for treating hypervolemia in ADHF and acute cardiorenal syndrome.
Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods.
TLDR
Chronic diuretic use was associated with increased long-term mortality and hospitalizations in a wide spectrum of ambulatory chronic systolic and diastolic HF patients, challenging the wisdom of routine chronic use of diuretics in HF patients who are asymptomatic or minimally symptomatic without fluid retention.
Relation between dose of loop diuretics and outcomes in a heart failure population: Results of the ESCAPE Trial
We examined the relation of maximal in‐hospital diuretic dose to weight loss, changes in renal function, and mortality in hospitalised heart failure (HF) patients.
Diuretics and ultrafiltration in acute decompensated heart failure.
TLDR
This review summarizes available data on the use of both diuretics and UF in ADHF patients and identifies challenges and unresolved questions for each approach.
Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.
TLDR
The decrease in body weight with tolvaptan was not associated with changes in heart rate or blood pressure, nor did it result in hypokalemia or worsening renal function.
...
1
2
3
4
5
...